This case-based article and video series explores recent perspectives on treatment strategies around clinical case profiles.
December 22nd 2022
This roundtable series reviews immunotherapy in patients with unresectable hepatocellular carcinoma as first-line treatment, as discussed by key opinion leaders and participants at virtual live events.
December 19th 2022
This roundtable series evaluates the use of frontline immunotherapy plus chemotherapy in locally advanced or metastatic biliary tract cancer, as discussed by key opinion leaders and participants at virtual live events.
December 7th 2022
This roundtable series provides context on the growing number of options for patients with non–small cell lung cancer and KRAS G12C mutations, as discussed by key opinion leaders and participants at virtual live events.
November 23rd 2022
This roundtable series assesses later-line treatment of patientswith relapsed/refractory multiple myeloma, as discussed by key opinion leaders and participants at virtual live events.
October 31st 2022
This roundtable series explores combination treatments for patients with upper gastrointestinal cancer, as discussed by key opinion leaders and participants at virtual live events.
September 28th 2022
This roundtable series discusses blastic plasmacytoid dendritic cell neoplasms in patients and the ways to identify and provide therapy for this rare disease, as discussed by key opinion leaders and participants at virtual live events.
September 16th 2022
This roundtable series considers multiple therapies from published clinical trials for patients with relapsed/refractory metastatic clear cell renal cell carcinoma, as discussed by key opinion leaders and participants at virtual live events.
September 14th 2022
This roundtable series reviews molecular testing in non–small cell lung cancer and potential treatments for patients with EGFR exon 20 mutations, as discussed by key opinion leaders and participants at virtual live events.
September 13th 2022
This roundtable series provides insights on assessing patients with renal cell carcinoma and how to treat them in the first line based on their risk factors, as discussed by experts in video interviews with Targeted Oncology.
July 25th 2022
This roundtable series evaluates radioligand therapy in patients with previously treated metastatic castration-resistant prostate cancer with positive prostate-specific membrane antigen, as discussed by participants at virtual live events.